Icon welcomes Dr Nat Lenzo

Icon Writers / 23 Apr, 2024

Icon Group is thrilled to welcome Dr Nat Lenzo who has joined our clinical team as Clinical Director, Molecular Imaging and Nuclear Oncology (Asia Pacific).

Dr Lenzo is a highly experienced and internationally recognised Nuclear Oncologist and Internal Medicine Physician with more than 25 years’ experience in specialised nuclear oncology. He has a strong interest in research with over 60 peer-reviewed publications specialising in molecular imaging and targeted therapies.

In 2015, Nat founded Theranostics Australia, the nation’s first private Theranostics practice where he worked as a group clinical director and expanded the field of nuclear oncology globally. He has held significant positions such as Head of Nuclear Medicine at Royal Perth Hospital, Head of the Western Australia PET Cyclotron Service at Sir Charles Gairdner Hospital, and Head of General Medicine at Fremantle Hospital.

He is also the Founding Director of Cyclowest, a start-up cyclotron and radiopharmaceutical company with a strong focus on patient care and cutting-edge innovative molecular imaging research.

Future healthcare

Icon Chief Medical Officer, Dr Ian Irving says Dr Lenzo will continue to grow Icon’s Theranostics program.

“Last year we launched our first Theranostics program at Icon North Lakes in Queensland with the intention to expand services across Australia and beyond,” said Dr Irving.

“Nat’s wealth of experience, international reputation and dedication to patient care will drive forward our precision medicine capabilities and allow us to deliver Theranostics to more people globally.”

Dr Lenzo joins Icon’s growing network of over 350 specialised clinicians and highlights a commitment to investing in the future of healthcare.

Icon Group CEO, Mark Middleton says this a reflection of Icon’s doctor-led foundations.

“Icon is a clinician founded and led organisation, and while we have grown significantly in a short amount of time, our values remain the same,” said Mark.

“We are very fortunate to have the trust of our experienced doctors and an ever-growing global network of clinicians who are dedicated to providing the best possible care to our patients.”

Patient focus

Dr Lenzo says he chose Icon for its commitment to patient care.

“Icon’s comprehensive and innovative approach to cancer care aligns with my personal practice and commitment to providing a positive patient experience,” said Dr Lenzo.

“Nuclear oncology and precision medicine is fast becoming a critical pillar in cancer treatment and Icon has shown a commitment to being early adopters of new and emerging treatments.

“I want to be part of this story and provide greater opportunities for people not just in Australia, but globally to access precision medicine and hopefully provide better patient outcomes now and in the future.”

Global growth

Dr Lenzo will work closely with Nuclear Medicine Physician, A/Prof David Macfarlane who leads our Theranostics program at Icon Cancer Centre North Lakes in Queensland and will continue to expand the group’s Theranostics offering both nationally and internationally.

He will be based at his private clinic in Murdoch, Western Australia and consult patients with general medical needs who require specialised oncology. He will treat at Icon Cancer Centre North Lakes, with a view to begin treating more patients across the eastern seaboard and at Icon’s Singapore location and beyond.

Learn more about Theranostics here.

View all News


Contact us